Search

Your search keyword '"Seiedeh Bentolhoda Mousavi"' showing total 4 results
Start Over Author "Seiedeh Bentolhoda Mousavi" Publication Year Range Last 50 years
4 results on '"Seiedeh Bentolhoda Mousavi"'

1. Comparison of Caregivers’ Burden among Family Members of Patients with Severe Mental Disorders and Patients with Substance Use Disorder

Author

Ronak Mihan, Seiedeh Bentolhoda Mousavi, Mohammad Reza Khodaie Ardakani, Hamed Rezaei, Samaneh Hosseinzadeh, and Rosa Alikhani

Subjects
Caregiver Burden, Severe Mental Disorders, Substance Use Disorder, Psychiatry, RC435-571
Abstract

Objective: The burden on caregivers of patients with severe mental disorders is significantly higher than the care burden of patients with other medical conditions. Substance use disorder is also one of the most common psychiatric disorders that has negative effects on people's quality of life. This study was designed to investigate caregiver burden in severe mental disorders versus substance use disorder. Method: First-degree relatives of patients admitted to the Razi Psychiatric Hospital of Tehran with a diagnosis of schizophrenia, bipolar disorder type1, schizoaffective disorder, or substance use disorder entered this study. They completed the sociodemographic questionnaire for patients and caregivers and the Zarit burden interview for caregivers. Results: Our study shows that caregiver burden in substance use disorder has no significant difference with that in severe mental disorders (P > 0.05). In both groups, the highest spectrum of burden was moderate to severe. To find caregiver burden related factors, a general linear regression model with multiple predictor variables was fitted. In this model, caregivers’ burden was significantly higher in patients with comorbidity (P = 0.007), poor compliance (P < 0.001), and in female caregivers (P = 0.013). Conclusion: Statistically speaking, the caregiver burden in substance use disorders is as severe as other mental disorders. The considerable burden on both groups necessitates serious efforts to minimize its negative effects.

Published
2023
Full Text
View/download PDF

2. Virtual Reality Videos and Their Effect on Adolescent Anxiety during Orthodontic Treatments: A Parallel Randomized Controlled Trial

Author

Mahjoube Goldani Moghadam, Sadegh Hosseini Sede, Seiedeh Bentolhoda Mousavi, Saeid Mohtasham, Alireza Ehteshampour, Rosa Alikhani, Hamed Aramjoo, and Majid Zare_Bidaki

Subjects
virtual reality, multimedia, dental anxiety, orthodontics, children, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

Background: Fear of dental procedures is one of the main reasons why patients tend to avoid dental clinics. The present study aimed to investigate the effect of using Virtual Reality (VR) videos during dental treatments on anxiety levels of the adolescents receiving treatment in dental clinics. Methods: A total of 66 patients aged 12-15 years were referred to the dental clinic at the Orthodontic Department of Birjand University of Medical Sciences. The participants were randomly assigned to two groups (n=33). The patients in the experimental group were engaged in watching a VR clip using a headset, while the control group directly observed the treatment procedure. Beck Anxiety Inventory (BAI) was administered to measure the participants’ anxiety before and after the treatment. SPSS (Version 22) was used to analyze the data. Results: The results of Mann-Whitney U test revealed a statistically significant difference between the anxiety levels of the participants in experimental and control groups (P=0.014). However, the results of Spearman Correlation test did not suggest any significant direct correlation between the participants’ age and anxiety scores after the intervention in control (r=0.002, P=0.992) and experimental (r=0.2755, P=0.122) groups. Additionally, the results of the MannWhitney U test indicated that there was no statistically significant difference between gender and anxiety scores after the intervention in the control (P=0.203) and experimental (P=0.207) groups. Conclusion: The results of the present study showed that the patients receiving VR distraction revealed lower anxiety caused by orthodontic procedures. This finding implies the effectiveness of the VR-based techniques to reduce anxiety during dental treatments.

Published
2021
Full Text
View/download PDF

3. Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial

Author

Areoo Samaei, Amir Ashraf-Ganjouei, Farzin Rezaei, Sayna Bagheri, Rosa Alikhani, Seiedeh Bentolhoda Mousavi, Kamyar Moradi, and Shahin Akhondzadeh

Subjects
Adult, Male, medicine.medical_specialty, AcademicSubjects/MED00415, Placebo-controlled study, resveratrol, Placebo, Regular Research Articles, Antioxidants, Extrapyramidal symptoms, Double-Blind Method, Internal medicine, Outcome Assessment, Health Care, medicine, Humans, Pharmacology (medical), Pharmacology, Risperidone, Positive and Negative Syndrome Scale, business.industry, AcademicSubjects/SCI01870, primary negative symptoms, clinical trial, Middle Aged, medicine.disease, Clinical trial, schizophrenia, Psychiatry and Mental health, Tolerability, Schizophrenia, Drug Therapy, Combination, Female, medicine.symptom, business, medicine.drug, Antipsychotic Agents
Abstract

Background Patients with schizophrenia can generally manifest a broad variety of primary negative symptoms. The current study aimed to assess the efficacy and tolerability of resveratrol add-on therapy in the treatment of negative symptoms in patients with stable schizophrenia. Methods In a randomized, double-blind, and placebo-controlled setting, schizophrenia patients were assigned to receive either 200 mg/d resveratrol or matched placebo in addition to a stable dose of risperidone for 8 weeks. Patients were assessed using the positive and negative syndrome scale, the extrapyramidal symptom rating scale, and Hamilton Depression Rating Scale over the trial period. The primary outcome was considered as the change in positive and negative subscale score from baseline to week 8 between the treatment arms. Results A total 52 patients completed the trial (26 in each arm). Baseline characteristics of both groups were statistically similar (P > .05). Despite the statistically similar behavior of positive symptoms between the groups across time (Greenhouse-Geisser corrected: F = 1.76, df = 1.88, P = .180), the resveratrol group demonstrated greater improvement in negative, general psychopathology, and total scores (Greenhouse-Geisser corrected: F = 12.25, df = 2.04, P Conclusion Adding resveratrol to risperidone can exhibit remarkable efficacy and safety in terms of management of schizophrenia-related negative symptoms.

Published
2020

4. 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control

Author

Salomeh Ghaffari, Ali Aqamolaei, Ahmad Shamabadi, Mohammd Reza Shalbafan, Sina Naderi, Shahin Akhondzadeh, Rosa Alikhani, Seyyed Hosein Mortazavi, Erfan Sahebolzamani, Seiedeh Bentolhoda Mousavi, Shakiba Jalilevand, Arash Sadri, Amirhosein Mortezaei, and Farzaneh Yousefzadeh

Subjects
Adult, Male, Obsessive-Compulsive Disorder, medicine.medical_specialty, Placebo, law.invention, 5-Hydroxytryptophan, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pharmacotherapy, Double-Blind Method, Randomized controlled trial, law, Internal medicine, medicine, Adjuvant therapy, Humans, Pharmacology (medical), Young adult, Fluoxetine, business.industry, Repeated measures design, 030227 psychiatry, Psychiatry and Mental health, Treatment Outcome, chemistry, Fluvoxamine, Drug Therapy, Combination, Female, business, 030217 neurology & neurosurgery, medicine.drug
Abstract

On the basis of numerous previous studies, the serotonergic system plays a role in the pathogenesis of obsessive-compulsive disorder (OCD) and effective agents in this pathway, such as 5-hydroxytryptophan, can potentially contribute to treatment of patients with this disorder. Evaluating the efficacy of 5-hydroxytryptophan in treating OCD was the aim of the present randomized, double-blind, placebo-controlled 12-week trial. In a 12-week, randomized double-blind study, 60 patients with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of moderate to severe OCD and a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of >21 were randomly assigned to receive either fluoxetine plus placebo or fluoxetine plus 5-hydroxytryptophan (100 mg twice daily). All patients, regardless of their treatment group, received fluoxetine at 20 mg/day for the initial 4 weeks of the study followed by 60 mg/day of fluoxetine for the rest of the trial course. Symptoms were assessed using the Y-BOCS at baseline and weeks 4, 8 and 12. General linear model repeated measure showed significant effects for time × treatment interaction on total Y-BOCS (F = 12.07, df = 2.29, P-value

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results